Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson selected a vaccine to take to Phase 3. Another rival amyloid beta antibody could appear on the market next year.

Johnson & Johnson: Alzheimer's Disease Pipeline Could Dominate

Allstate

Home Depot

Iron Mountain

Kinder Morgan

Kroger

The concept of targeting iron-clad stocks to buy for volatility might seem overkill. After all, the Labor Department just revealed that the U.S. economy added 263,000 jobs, above analysts' expectations.

7 Iron-Clad Stocks That Will Resist the Market Turmoil

The stock for this healthcare stalwart beat the S&P 500's performance over the past decade.

If You Bought 100 Shares of Johnson & Johnson 10 Years Ago, This Is How Much You Would Have Today

Amgen

Sanofi

Johnson & Johnson dropped out of the bidding process for Horizon Therapeutics, pushing HZNP stock into the red on Monday. The post Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi appeared first on Investor's Business Daily.

Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi

Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

Is Johnson & Johnson Stock A Better Pick Over Its Peer?

JNJ will be spinning off its popular consumer health segment into a separate company called Kenvue. Medical Devices and Pharmaceutical segments will remain together in which they are the fastest growing segments within the business.

Johnson & Johnson: Time To Buy Before The Split

Some stocks are exciting, and they can offer outsized returns over the long run. However, it's sometimes hard to pick which newer stocks will be winners, and it's possible to lose money trying to pick long-term winners.

Johnson & Johnson: Boring, But Worth Having In A Portfolio

AbbVie

Celsius Holdings

Copa Hlds

Equinor

Genmab - ADR

Horizon Pharma

Lattice Semiconductor

Monster Beverage

PepsiCo

Seagen

An array of top stocks in a wide variety of industries are building cup bases as the stock market recovers. The post Top Stocks In Multiple Industries Build Bases As Market Gains Strength appeared first on Investor's Business Daily.

Top Stocks In Multiple Industries Build Bases As Market Gains Strength

Apple

Kraft Heinz

Taiwan Semiconductor Manufacturing

U.S. Bancorp

Visa

Warren Buffett (Trades, Portfolio), the legendary investor who leads Berkshire Hathaway (BRK.A)(BRK.B), is known for his preference of investing in wonderful companies at fair prices that have strong competitive advantages and predictable businesses. This long-term strategy has contributed to his strong performance of an average annual return of 20% since 1965.

Warren Buffett and David Rolfe Agree on These 6 Stocks

Edwards Lifesciences

Intuitive Surgical

Eli Lilly

Merck

Walgreens

Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morning.

Gurus Prescribed These Health Care Stocks in the 3rd Quarter

NEW BRUNSWICK, N.J.--( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Chief Executive Officer, Mr. Joaquin Duato, to assume the additional position of Chairman, effective in January 2023. Mr. Duato succeeds Mr. Alex Gorsky, who will step down from his role as Executive Chairman following a brief transitional period.

Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board

McKesson

Procter & Gamble

These stocks could grow Buffett's wealth -- and yours.

3 Warren Buffett Stocks to Buy Hand Over Fist Before 2023

Horizon said Tuesday it's considering potential offers from three Big Pharma stalwarts, sending HZNP stock soaring more than 30% after hours. The post Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi appeared first on Investor's Business Daily.

Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi

J & J Snack Foods

Ulta Beauty

World Wrestling Entertainment

World Wresting Entertainment, J&J Snack Foods and Ulta Beauty Inc are having a great year if you go by stock price increase.

Odd Assortment Of New 52-Week Highs: World Wrestling Entertainment, J&J Snack Foods And Ulta Beauty

2 top health care dividend stocks to check out ahead of December 2022.

Best Dividend Stocks To Buy Now? 2 To Watch Before December 2022

Bristol-Myers

These businesses -- and dividends -- are built to last.

3 Dividend Stocks to Hold Forever

These businesses may not be "exciting," but that's not such a bad thing right now.

2 Safe Dividend Stocks to Buy Hand Over Fist

JPMorgan Chase & Co

Coca-Cola

Marcus & Millichap

Sociedad Quimica Y Minera De Chile

Safe haven investments are a great way to lower risk over the long haul. Companies with consistent revenue and earnings tend to be more stable and help significantly lower risk during volatile market conditions.

7 Must-Own Safe Havens as Market Selloff Accelerates

Elevance Health Inc

MercadoLibre

QUALCOMM

Raytheon Technologies

Walmart

Large-cap stocks are always great to have in a portfolio. These companies are some of the biggest and best-known stocks in the market.

News for Johnson & Johnson Stock (JNJ)